Fecal Microbiota Transplantation in Patients Undergoing Chimeric Antigen Receptor T-cell Therapy and Allogeneic Stem Cell Transplant: A Pilot Study
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a single site pilot trial will evaluate the feasibility and safety of fecal microbiota transplantation (FMT) in patients with B-cell lymphoma who are undergoing CAR-T or in patients with moderate to high-risk acute myeloid leukemia or myelodysplastic syndrome who are undergoing allogeneic stem cell transplantation.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Diagnoza chłoniaka typu B lub białaczki ostrej (AML) albo zespołu mielodysplastycznego wysokiego ryzyka
- •Dobry stan ogólny (mobilny, samodzielny w czynnościach dnia codziennego)
- •Odpowiednia liczba krwinek: hemoglobina powyżej 80, płytki powyżej 20, białe krwinki powyżej 1,0
- •Prawidłowa praca wątroby (markery wątrobowe w normie)
- •Prawidłowa praca nerek (klirens kreatyniny co najmniej 30 mL/min)
- •Oczekiwana długość życia ponad 6 miesięcy
- •Gotowość do zastosowania antykoncepcji podczas leczenia i przez 6 miesięcy po nim
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 8, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
University Health Network
Toronto, Canada
Trial contact
Abi Vijenthira, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/9/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.